TRIPASS XR تري باس

 

References

Ali, M. & McDonald, J. W. D. (1977). Effects of sulphinpyrazone on platelet prostagiandin

synthesis and platelet release ofserotonin. J.lab. clin. Med., 89, 868-875.

AlIy, A, 1., Manku, M, S., Horrobin, D. F., Morgan , R. 0 ., Karmazin, M. & Karmali, R. A,

(1977). Dipyridamole: A possible potent inhibitor of thromboxane A2 synthetase in

vascular smooth museIe. Prostaglandins, 14, 607-{)09.

Arfors, K. E., Bergqvist, D. & Tangen, O. (1975). The effect of platelet function inhibitors on

experimental venous thrombosis formation in rabbits. Acta Chir. Scand. , 141,40-42.

Baenziger , N. L., Dillender, M. J. & Majerus , P. W. (1977).Cultured human skin fibroblasts and

arterial cells produce a labile platelet-inhibitory prostaglandin. Biochem. Biophys. Res.

Commun., 78,294-301.

Best, L. c., McGuier, M. B., Jones, P. B. B., Holland, T, K., Martin, T. J" Preston, F. E., Segal,

D. S, & RusselI, R. G , G , (1979), Mode of action of dipyridamole on human platelets,

Thromb. Res., 16,367-379.

Browse, N. L. & Hall , J. H. (1969). Effect of dipyridamole on the incidence of e1inically

detectable deep vein thrombosis. Lancet , 2, 718-721.

Buchanan, M. R. & Hirsh, J. (1978). A comparison ofthe effects ofaspirin and dipyridamole on

platelet aggregation in vivoand ex vivo. Thromb. Res., 13,517-529,

Buchanan, M, R., Rosenfeld, J. & Hirsh, J, (1978). The prolonged effect ofsulphinpyrazone on

collagen-induced platelet aggregation in vivo. Thromb . Res., 13,883-892,

Carter, A, E., Eban , R, & Perrett, R. D. (1971). Prevention of postoperative deep venous

thrombosis and pulmonary embolism. Brit. med. J.. 1,312-314.

Carter, A. E. & Eban , R. (1974). Prevention of postoperative deep venous thrombosis in legs by

orally administered hydroxychloroquine sulphate. Brit. med. J.. 3,94-95.

VENOUS THROMBOEMBOLlSM AND ANTIPLATELET DR UGS 231

Chrisman, O. D., Snook, G . A., Wilson, T . C. & Short, J. Y. (\976). Prevention of venous

thromboembolism by administration of hydroxychloroquine. J. Bone Joint Surg.. 58,

918-920.

Clagett, G . P., Brier, D. F., Rosoff, C. B., Schneider, P. B. & Salzman , E. W. (\974). Effect of

aspirin on postoperative platelet kinetics and venous thrombosis. Surg. Forum, 25,

473-476.

Clagett, G . P., Schneider, P., Rosoff, C. B. & Salzman. E. W. (\975). The influence ofaspirin on

postoperative platelet kinetics and venous thrombosis. Surgery, 77,61-74.

Cooke, E. D., Dawson, M. H. 0 ., Ibbotson, R. M., Bowcock, S. A., Ainsworth, M. E. & Pilcher,

M. F. (\977). Failure of orally administered hydroxychloroquine sulphate to prevent

venous thromboembolism following elective hip operations. 1. Bone Joint Surg., 59,

496-500.

Cucuianu, M. P., Nishizawa, E. E. & Mustard, J. F. (\971). Effect of pyridimo-pyrimidine

compounds on platelet function .1. lab.clin. Med.. 77,958-974.

Davies, J. A., Essien, E., Cazenave, J. P., Kinlough-Rathbone, R. L., Gent, M. & Mustard,J. F.

(1979). The influence of red blood cells on the effects of aspirin or sulphinpyrazone on

platelet adherence to damaged rabbit aorta. Brit.1. Haematol, 42, 283-291.

Dechavanne, M., Ville , D., Viala ,J. J., Kher, A., Faivre, J., Pousset, M. B. & Dejour, H. (1975).

Controlled trial ofplatelet anti-aggregating agcnts and subcutaneous heparin in prevention

ofpostoperative deep vein thrombosis in high risk patients. Haemostasis, 4, 94-100.

Emmons, P. R., Harrison, M. J. G., Honour, A. J. & MitchelI, J. R. A. (\965). Effect of

dipyridamole on human platelet behaviour. Lancet, 2,603-606.

Genton, E., Gent, M., Hirsh, J. & Harker, L. A. (\9 75). Platelet-inhibiting drugs in the

prevention ofclinical thrombotic disease. New Eng. 1. Med., 293, 1174-1178.

Gruber, U. F., Fuser, P., Frick, J., Loosli , J., Matt, E. & Segessar, D. (1977). Sulphinpyrazone

and postoperative deep vein thrombosis. Eur. S urg. Res., 9,303-310.

Hansen , E. H., Jessing, P., Lindewald. H., Ostergaard, P., Olesen, T . & Malver. E. I. (\976).

Hydroxychloroquine sulphate in prevention of deep venous thrombosis following fracture

ofthe hip , pelvis or thoracolumbar spine. 1. Bone Joint Surg. , 58 , 1089-1092.

Harker, L. A. & Slichter, S. J. (\972). Platelet and fibrinogen consumption in man . New Eng. J.

Med., 287,999-1005.

Harker, L. A. & Slichter, S. J., Scott, C. R. & Ross, R. (\974). Homocystinernia; vascular injury

and arterial thrombosis. New Eng. J. Med., 291,537-543.

Harris, W. H., Salzrnan, E. W., Athanasoulis, C. A., Waltman, A. C, Baum, S. & DeSanctis,

R. W. (\974). Comparison of warfarin, low-molecular weight dextran, aspirin and

subcutaneous heparin in prevention of venous thromboembolism following total hip

replacement. J. Bone Joint Surg. , 56, 1552-1562.

Harris, W. H., Salzrnan, E. W., Athanasoulis, C. A., Waltrnan, A. C. & DcSanctis, R. W. (\977).

Aspirin prophylaxis ofvenous thromboembolism after total hip replacement. New Eng. 1.

Med., 297, 1246-1249.

Hull, R. & Hirsh, J. (\9 79). Diagnosis ofvenous thrombosis. Mod. Med. Can ., 34,850-855.

Hurne, M., Bierbaum, V., Kuriakose, T . X. & Surprenant,J. (\977). Prevention ofpostoperative

thrombosis by aspirin. Am. J. Surg., 133,420-422.

Jennings, J. J., Harris, W. H. & Sarrniento, A. (1976). A clinical evaluation of aspirin

prophylaxis of thromboembolic disease after total hip arthroplasty. J. Bone Joint Surg.,

58,926-928.

Jergensen, K. A. & Stoffersen, E. (\978). Dipyridamole and platelet function . Lancet. 2, 1258.

Kelton, J. G., Hirsh, J., Carter, C. J. & Buchanan, M. R. (\978). Thrombogenic effect of

high-dose aspirin in rabbits. 1. clin. lnvest., 62, 892-895.

Madow, B. W. (\960). Use of antimalar ial drugs as 'desludging' agents in vascular disease

processes. J. Am. med. Ass.. 172, 1630.

McKenna, R., Galante, J., Bachman, F., Wallace. D. L., Kaushal, S. P. & Meredith, P. (\980).

Prevention ofvenous thromboembolism after total knee replacement by high-dose aspirin

or intermittent calfand thigh compression. Brit. med. J., 514-517.

Medical Research Council (Report of the Steering Committee) (\972). Eflect of aspirin on

postoperative venous thrombosis. Lancet, 2,441-445.

Mielke, C. H., Ramos, J. C. & Britten, A. F. H. (1973). Aspirin as an antiplatelet agent: template

bleeding time as a monitor oftherapy. Am. J. clin. Path.. 59,236-242.

Mills, D. C. & Smith, J. B. (\971). The influence of platelet aggregation of drugs that affect

accumulation ofadenosine 3':5' cyclic monophosphate in platelets. Bioehern. J., 121, 185.

232 A. G. G. TURPIE

Moncada, S., Higgs, E. A. & Vane, J. R. (1977). Human arterial and venous tissues generate

prostacyclin (prostagIandin X), a potent inhibitor ofplatelet aggregation. Lancet,1, 18-20.

Moncada, S. & Korbut, R. (1978). Dipyridamole and other phosphodiesterase inhibitors act as

antithrombotic agents in potentiating endogenous prostacyclin. Lancet, 1, 1286-1289.

Morris, C. K. & MitcheII, J. R. A. (1977). Preventing venous thromboembolism in elderly

patients with hip fractures ; studies of low dose heparin, dipyridamole, aspirin and

flurbiprofen. Brit. med. J.. 1, 535-537.

O'Brien, J. R., Tulevski, V. & Etherington, M. (1971). Two in vivo studies comparing high and

low aspirin dosage. Lancet, 1, 399-400.

Paterson, J. C. (1969). The pathology of venous thrombi. In Thrombosis, ed. Sherry, S.,

Brinkhous, K. M., Genton, E. & Stengle, J. M., pp. 321-331. Washington D.C.: National

Academy ofSciences.

Patersen, J. & Zucker, M. D. (1970). The effect of adenosine monophosphate, arcaine and

anti-inflammatory agents on thrombosis and platelet function in rabbits. Thromb. Diath .

Flaemorr.. 23, 148-158.

Pilcher, D. B. (1975). Hydroxychloroquine sulfate in prevention of thromboembolic

phenomena in surgical patients. Am. Surgeon. 41, 761-766.